Zydus Lifesciences Q2 Net Profit Falls 26.6% Amid Revenue Growth and Rising Expenses
Zydus Lifesciences reported a 26.6-27 percent decline in consolidated net profit to around Rs 925 crore in Q2 FY27, despite a 29 percent rise in revenue to approximately Rs 7,910 crore. The profit drop was attributed to a sharp increase in expenses, including higher R&D and employee costs. The pharma segment contributed 83 percent of sales, with India and North America formulations growing 18 and 21 percent respectively. The company highlighted growth in branded sales and progress in its specialty drug pipeline, including the upcoming US launch of Saroglitazar.
First-hand measurement across 7 sources
We measured how 7 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (47/100). Lens Score 41/100.
Outlets measured: economictimes, economictimes, moneycontrol, businessstandard, news18, businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (38–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Nov, 09:45 am. Other outlets followed.